相似文献
1
Effectiveness of long-acting injectable antipsychotics: a clinical perspective.
Evid Based Ment Health. 2015 May;18(2):36-9. doi: 10.1136/eb-2015-102086. Epub 2015 Apr 8.
2
Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
J Med Econ. 2018 Feb;21(2):127-134. doi: 10.1080/13696998.2017.1379412. Epub 2017 Sep 29.
3
Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?
J Clin Psychiatry. 2018 Jan/Feb;79(1). doi: 10.4088/JCP.AL17017WC1C.
4
Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics.
Eur Psychiatry. 2014 Nov;29 Suppl 2:1409-13. doi: 10.1016/S0924-9338(14)70001-X. Epub 2014 Nov 22.
5
Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
J Manag Care Spec Pharm. 2015 Sep;21(9):754-68. doi: 10.18553/jmcp.2015.21.9.754.
6
Long-acting injectable antipsychotics treatment during COVID-19 pandemic - A new challenge.
Schizophr Res. 2020 Jun;220:265-266. doi: 10.1016/j.schres.2020.04.030. Epub 2020 Apr 27.
7
First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies.
Br J Psychiatry Suppl. 2009 Nov;52:S20-8. doi: 10.1192/bjp.195.52.s20.
8
Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
Int Clin Psychopharmacol. 2013 Jul;28(4):164-70. doi: 10.1097/YIC.0b013e3283611cc3.
9
Financial impact of a pharmacist-managed clinic for long-acting injectable antipsychotics.
Am J Health Syst Pharm. 2012 Jun 15;69(12):1014-5. doi: 10.2146/ajhp110647.
10
Oral Antipsychotic Versus Long-Acting Injections Antipsychotic in Schizophrenia Spectrum Disorder: a Mirror Analysis in a Real-World Clinical Setting.
Psychopharmacol Bull. 2019 Jun 20;49(2):17-27.
引用本文的文献
1
Long-Acting Injectable Antipsychotics-A Review on Formulation and In Vitro Dissolution.
Pharmaceutics. 2023 Dec 24;16(1):28. doi: 10.3390/pharmaceutics16010028.
2
A comprehensive review of prioritised interventions to improve the health and wellbeing of persons with lived experience of homelessness.
Campbell Syst Rev. 2021 Jun 24;17(2):e1154. doi: 10.1002/cl2.1154. eCollection 2021 Jun.
3
Fluphenazine decanoate-induced bradycardia: A case report.
Neuropsychopharmacol Rep. 2022 Sep;42(3):368-373. doi: 10.1002/npr2.12251. Epub 2022 Apr 3.
4
Assessing Outcomes Between Risperidone Microspheres and Paliperidone Palmitate Long-Acting Injectable Antipsychotics Among Veterans.
Fed Pract. 2021 Dec;38(12):586-591. doi: 10.12788/fp.0195. Epub 2021 Dec 12.
5
Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health.
NPJ Schizophr. 2021 Apr 26;7(1):22. doi: 10.1038/s41537-021-00151-6.
6
Attitudes of European physicians towards the use of long-acting injectable antipsychotics.
BMC Psychiatry. 2020 Mar 14;20(1):123. doi: 10.1186/s12888-020-02530-2.
7
Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres.
PLoS One. 2019 Feb 15;14(2):e0211938. doi: 10.1371/journal.pone.0211938. eCollection 2019.
8
Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting.
Neuropsychiatr Dis Treat. 2019 Jan 7;15:183-198. doi: 10.2147/NDT.S189245. eCollection 2019.
9
Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
Psychopharmacol Bull. 2018 Mar 13;48(3):8-15.
10
Preparation and in vitro/in vivo evaluation of PLGA microspheres containing norquetiapine for long-acting injection.
Drug Des Devel Ther. 2018 Apr 5;12:711-719. doi: 10.2147/DDDT.S151437. eCollection 2018.
本文引用的文献
1
Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.
Schizophr Bull. 2015 Mar;41(2):449-59. doi: 10.1093/schbul/sbu067. Epub 2014 May 27.
2
Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.
JAMA. 2014 May 21;311(19):1978-87. doi: 10.1001/jama.2014.4310.
3
Maintenance treatment with long-acting injectable antipsychotics: comparing old with new.
JAMA. 2014 May 21;311(19):1973-4. doi: 10.1001/jama.2014.4311.
4
Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.
J Nerv Ment Dis. 2014 Jan;202(1):18-24. doi: 10.1097/NMD.0000000000000065.
5
Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
J Clin Psychiatry. 2013 Jun;74(6):568-75. doi: 10.4088/JCP.12r08167. Epub 2013 Apr 19.
6
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Lancet. 2013 Sep 14;382(9896):951-62. doi: 10.1016/S0140-6736(13)60733-3. Epub 2013 Jun 27.
7
Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.
BMC Psychiatry. 2013 May 30;13:155. doi: 10.1186/1471-244X-13-155.
8
Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.
Schizophr Bull. 2014 Jan;40(1):192-213. doi: 10.1093/schbul/sbs150. Epub 2012 Dec 17.
9
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.
Lancet. 2012 Jun 2;379(9831):2063-71. doi: 10.1016/S0140-6736(12)60239-6. Epub 2012 May 3.
10
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
J Clin Psychiatry. 2012 May;73(5):669-75. doi: 10.4088/JCP.11m07074. Epub 2012 Mar 6.
Zotero 插件